Recent studies of paclitaxel DCB in the treatment of stenosis at dialysis vascular access have shown promising results. Paclitaxel, an anti-proliferation drug, is released during balloon inflation and potentially improve primary patency by slowing down NIH effect. However, meta-analysis have suggested that the use of paclitaxel in lower limbs have increased risk of death in patients. The effect of paclitaxel DCB on dialysis access however remains unknown. Hence, we aim to set up a database to track long-term treatment outcomes of patients treated with Paclitaxel DCB at SGH for their stenosed dialysis access
Study Type
OBSERVATIONAL
Enrollment
500
Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
Singapore General Hospital
Singapore, Singapore
RECRUITINGCircuit Access Patency
Circuit Access Patency is lost when AVF/AVG is intervened on
Time frame: 12 Months
Primary Assisted Patency
Primary Assisted Patency is lost when circuit undergoes thrombectromy/thrombolysis
Time frame: 12 months
Secondary Patency
Secondary Patency is lost when entire dialysis access circuit is abandoned.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.